Brought to you by 
PhaseBio brings in $40mm in Series C financing led by AstraZeneca
17 Oct 2018
Executive Summary
PhaseBio Pharmaceuticals Inc. (metabolic and cardiopulmonary therapies) raised $40mm through its Series C financing led by AstraZeneca, which was joined by returning shareholders New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Development Corp., and Fletcher Spaght Ventures. Funds will help move into Phase IIa both its PE0139 for Type II diabetes and PB1046 for heart failure and cardiomyopathy in Duchenne and Becker muscular dystrophy. AstraZeneca’s Michael Gutch, PhD, takes a seat on PhaseBio's board, and Donald Dwyer joins as an observer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PhaseBio brings in $40mm in Series C financing led by AstraZeneca
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice